S&P Futures
4,054.25 -3.25 (-0.08%) Dow Futures
32,875.00 -28.00 (-0.09%) Nasdaq Futures
12,944.25 -20.75 (-0.16%) Russell 2000 Futures
1,781.50 -2.80 (-0.16%) Crude Oil
72.90 -0.07 (-0.10%) Gold
1,964.00 -2.90 (-0.15%)
Zealand Pharma A/S (ZEAL.CO)
- GlobeNewswire
Zealand Pharma's Annual General Meeting 2023
Company announcement – No. 9 / 2023 Zealand Pharma's Annual General Meeting 2023 Copenhagen, March 29, 2023 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2023 as a partly electronic general meeting. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2022 was
- GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 8 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 34,594 divided into 34,594 new shares with a nominal value of DKK 1 each. The increa
- GlobeNewswire
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapy for the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on t
